Anzeige
Meldung des Tages: Milliardenmarkt, eigene KI-Plattform, starke Kasse: Ist diese Aktie massiv unterbewertet?

Biogen News

Aktie
WKN:  789617 ISIN:  US09062X1037 US-Symbol:  BIIB Branche:  Pharmazeutika Land:  USA
191,83 $
+5,61 $
+3,01%
162,32 € 19.02.26
Depot/Watchlist
Marktkapitalisierung *
22,04 Mrd. €
Streubesitz
3,72%
KGV
11,76
Nachhaltigkeits-Score
49 %
Index-Zuordnung
Nasdaq 100
Weiter aufwärts? Long handeln - Jetzt mit Hebel 5,50: VH8CA6
Werbung

Biogen News

19.02.26 - dpa-AFX
Rückschlag für Alzheimer-Mittel Lecanemab von Eisai und Biogen
Für den Alzheimer-​Wirkstoff Lecanemab gibt es nach Ansicht eines entscheidenden Expertengremiums keinen belegten Zusatznutzen im Vergleich zu älteren ...
11.02.26 - GlobeNewswire
Biogen Announces Board Chair Transition
Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair
06.02.26 - wallstreetONLINE Redaktion
Ihre wichtigsten Termine: Frische Zahlen von Philip Morris, Under Armour, Toyota, Biogen, Societe Generale
Gut geplant in den Tag. Mit dem wO-​Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine ...
04.02.26 - GlobeNewswire
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both treatment-naïve individuals and those previously treated with 12 ...
28.01.26 - GlobeNewswire
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin ...
25.01.26 - PR Newswire
FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
FDA Accepts LEQEMBI® IQLIKTM (lecanemab-​irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease ...
12.01.26 - GlobeNewswire
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and previously-​treated ...
09.01.26 n-tv
Zollerleichterungen kommen: Mercosur-Deal könnte Fleisch, Obst und Kaffee günstiger machen
Zwischen Europa und den Mercosur-​Ländern Brasilien, Argentinien, Uruguay und Paraguay sollen Zölle abgebaut und der Handel ausgeweitet werden. Umweltschützer fürchten ...
22.12.25 - GlobeNewswire
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
Long-term data published in JAMA Neurology further illustrate the effects of Biogen’s QALSODY on function, strength, and survival in SOD1 -ALS Over 3 years, a subset of QALSODY-...
06.12.25 - wallstreetONLINE Redaktion
Gewinner der Börsengeschichte: +472.505 % seit dem IPO: Aus 1.000 wurden $4.725.050!
Die performenstärkste Aktie der letzten 25 Jahre ist nicht Monster Beverage, Altria oder Amphenol. Eine US-​Tech-Aktie ließ sie alle hinter sich. Seit dem Börsen­gang 1999 stieg der ...
05.12.25 - GlobeNewswire
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-​seizure medicines (ASMs) demonstrate durable seizure reductions, ...
03.12.25 - PR Newswire
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-​irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on ...
02.12.25 - PR Newswire
New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-​irmb) on Neurotoxic Aβ ...
02.12.25 - dpa-AFX
Institut: Alzheimer-Medikament Lecanemab von Biogen hat keinen Zusatznutzen
Schlechte Nachrichten für den US-​Hersteller Biogen und seinen japanischen Partner Eisai: Ein umfassender Report sieht keinen Beweis für einen Zusatznutzen ihres Alzheimer-...
25.11.25 - PR Newswire
Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-​irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the ...
24.11.25 - GlobeNewswire
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
Oral macrocyclic peptides have the potential to offer biologic-​like efficacy and safety in a convenient oral format Collaboration further advances Biogen’s immunology strategy by ...
17.11.25 - GlobeNewswire
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
– Despite treatment with standard-​of-care anti-​seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a ...
17.11.25 - GlobeNewswire
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-​naive participants and those transitioning from ...
14.11.25 - GlobeNewswire
Biogen Completes Acquisition of Alcyone Therapeutics
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-​stage biotechnology ...
03.11.25 - GlobeNewswire
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
Oral presentation to share first-​of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights into the mechanism of action of felzartamab and advancing ...

Newssuche

Videos

newspaper
25.02.26
So beeinflussen Margins DEIN Trading
Börsentäglich ab 18 Uhr Feierabend-​Trading Live. Teilnahme kostenlos mit diesem Link ... Mehr »